Lyra Therapeutics, Inc. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported net loss was USD 16.26 million compared to USD 11.91 million a year ago. Basic loss per share from continuing operations was USD 0.44 compared to USD 0.92 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.372 USD | +2.59% | -11.43% | -92.90% |
May. 07 | Jefferies Downgrades Lyra Therapeutics to Hold, Price Target at $0.50 | MT |
May. 07 | HC Wainwright Downgrades Lyra Therapeutics to Neutral From Buy | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-92.90% | 22.11M | |
+29.03% | 48.16B | |
-0.10% | 41.73B | |
+43.45% | 41.03B | |
-5.26% | 28.77B | |
+11.48% | 25.59B | |
-22.74% | 18.96B | |
+9.06% | 12.92B | |
+30.01% | 12.03B | |
-1.51% | 11.77B |
- Stock Market
- Equities
- LYRA Stock
- News Lyra Therapeutics, Inc.
- Lyra Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023